Frazier Life Sciences Management L.P. acquired a new position in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 1,120,803 shares of the company's stock, valued at approximately $14,761,000. Frazier Life Sciences Management L.P. owned approximately 1.84% of Pliant Therapeutics as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also modified their holdings of the business. R Squared Ltd purchased a new position in shares of Pliant Therapeutics during the 4th quarter valued at $33,000. Aquatic Capital Management LLC grew its holdings in Pliant Therapeutics by 1,299.0% during the fourth quarter. Aquatic Capital Management LLC now owns 5,596 shares of the company's stock valued at $74,000 after purchasing an additional 5,196 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Pliant Therapeutics in the 4th quarter valued at $99,000. KLP Kapitalforvaltning AS bought a new position in shares of Pliant Therapeutics in the fourth quarter worth about $108,000. Finally, Corton Capital Inc. bought a new stake in Pliant Therapeutics during the 4th quarter valued at approximately $138,000. Hedge funds and other institutional investors own 97.30% of the company's stock.
Pliant Therapeutics Stock Up 1.5%
Shares of Pliant Therapeutics stock opened at $1.37 on Wednesday. The stock has a market cap of $84.10 million, a PE ratio of -0.41 and a beta of 1.43. Pliant Therapeutics, Inc. has a 12 month low of $1.10 and a 12 month high of $16.10. The business has a fifty day simple moving average of $1.45 and a 200 day simple moving average of $7.22. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09.
Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($0.99) by $0.17. Research analysts predict that Pliant Therapeutics, Inc. will post -3.64 EPS for the current year.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the stock. Citigroup decreased their price target on shares of Pliant Therapeutics from $4.00 to $1.50 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. HC Wainwright reissued a "neutral" rating on shares of Pliant Therapeutics in a report on Tuesday, March 18th. Stifel Nicolaus downgraded shares of Pliant Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Canaccord Genuity Group reaffirmed a "hold" rating and set a $4.00 price target (down from $43.00) on shares of Pliant Therapeutics in a report on Monday, February 10th. Finally, Royal Bank of Canada reduced their target price on shares of Pliant Therapeutics from $4.00 to $3.00 and set a "sector perform" rating on the stock in a research report on Tuesday, March 4th. Twelve analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $13.31.
View Our Latest Stock Report on PLRX
About Pliant Therapeutics
(
Free Report)
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
Featured Articles
Want to see what other hedge funds are holding PLRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pliant Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pliant Therapeutics wasn't on the list.
While Pliant Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
